1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Immune Checkpoint Therapeutics - Hot Targets & Pipeline Analysis

Immune Checkpoint Therapeutics - Hot Targets & Pipeline Analysis

  • April 2016
  • -
  • IQ4I Research & Consultancy Pvt. Ltd
  • -
  • 161 pages

“IMMUNE CHECKPOINT THERAPEUTICS – HOT TARGETS & PIPELINE ANALYSIS” gives comprehensive insights on the various Immune Checkpoint modulators being developed for the treatment of various diseases. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins, Bi-specific Ab’s, Antibody drug conjugates, Cell therapy, Peptides, Oncolytic viruses and Vaccines.

The report also covers hot targets in research for Checkpoint modulators.
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Immune Checkpoints Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future Immune Checkpoint treatment space.

The report in addition to the monotherapy covers the pipeline for combination therapies associated only with checkpoint agents.
In order to effectively deal various diseases, the immune system needs to be able to generate an appropriate counter response. However, as a part of the natural fail–safe mechanism, to limit overactive immune responses that could lead to an auto-immune disease, there are a number of markers (“immune checkpoint receptors”) found on both tumor cells and antigen presenting cells (dendritic cells, macrophages etc.) that can down-regulate or suppress T cells once the corresponding ligand is bound.

Currently, Researchers are challenged to identify various avenues to prevent T cells from binding these tolerance-inducing ligands either through antibodies or recombinant forms of ligand or receptors. So, these T cells remain active and ready to tackle various diseases. Owing to its high response rate and prolonged overall patient survival the checkpoint therapeutics are gaining in popularity and have shown some impressive results in the areas of Oncology, Inflammation, Respiratory, Autoimmune and Infectious disease.

Table Of Contents

Immune Checkpoint Therapeutics - Hot Targets and Pipeline Analysis
-Emerging role of immunotherapy
-Immune checkpoints
-Immune checkpoints-Types
-Stimulatory checkpoint pathways
-Inhibitory checkpoint pathways
-Targets - Immune checkpoints -Other immune checkpoint targets
-Top companies based on revenue
-Top companies based on Pipeline
-Market dynamics
-Market sizing
-Immune checkpoint Deals
-Development stage
-Leading players
-Target analysis
-Therapeutic Segmentation
-Oncology immune checkpoint pipeline by indication
-Competitive landscape MONOCLONAL ANTIBODIES
-Competitive landscape BISPECIFIC ANTIBODIES
-Competitive landscape ANTIBODY DRUG CONJUGATES (ADC's)
-Competitive landscape
-Competitive landscape
-Company Profiles
-Overview, Pipeline and Deals

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.